Gyrase inhibitors and uses thereof

A method of controlling, treating or reducing the advancement, severity or effects of a nosocomial or a non-nosocomial bacterial infection in a patient, wherein the bacterial infection is characterized by the presence of one or more of the following:

• Methicillin resistant Staphylococci, Fluoroquinolone resistant Staphylococci, Glycopepetide resistant Staphylococci, Macrolide-Lincosamide-Streptogramin resistant Staphylococci, Linezolid resistant Enterococci, Glycopepetide resistant Enterococci, β-lactam resistant Enterococci, Penicillin resistant Streptococci, Macrolide resistant Streptococci, Ketolide resistant Streptococci, Fluoroquinolone resistant Streptococci, β-lactam resistant Haemophilus, Fluoroquinolone resistant Haemophilus, Macrolide resistant Haemophilus, Macrolide resistant Mycoplasma, Isoniazid resistant Mycobacterium, Rifampin resistant Mycobacterium, or β-lactam resistant Moraxella, comprising the step of administering to said patient a compound of formula I:
• or a pharmaceutically acceptable salt thereof, wherein:
• W is selected from CH or CF;
• X is selected from CH or CF;
• Z is O or NH;
• R1 is a 6 membered heteroaryl ring having 1-2 nitrogens, wherein:
• R1 is substituted with 0-3 groups independently selected from —(T)y—Ar, R′, oxo, C(O)R′, CO2R′, OR′, N(R′)2, SR′, NO2, halogen, CN, C(O)N(R′)2, NR′C(O)R′, SO2R′, SO2N(R′)2, or NR′SO2R′;
• y is 0 or 1;
• T is a straight or branched C1-4 alkylidene chain, wherein one methylene unit of T is optionally replaced by —O—, —NH—, or —S—;
• each R′ is independently selected from hydrogen, C1-4 aliphatic, or a 5-6 membered saturated, unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:
• R′ is substituted with 0-3 groups independently selected from halogen, oxo, Ro, N(Ro)2, ORo, CO2Ro, NRoC(O)Ro, C(O)N(Ro)2, SO2Ro, SO2N(Ro)2, or NRoSO2Ro, wherein:
• each Ro is independently selected from hydrogen, C1-4 aliphatic, or a 5-6 membered saturated, unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein:
• two substituents on adjacent positions of R1 may be taken together to form a 5-7 membered saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• Ar is a 5-6 membered saturated ring having 1-2 heteroatoms independently selected from oxygen, nitrogen or sulfur, a 5 membered heteroaryl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen or sulfur, a 6-membered heteroaryl ring having 1-3 nitrogens or a phenyl ring, wherein:
• Ar is substituted with 0-3 groups independently selected from R′, oxo, CO2R′, OR′, halogen, SO2R′, or C(O)R′;
• R2 is selected from hydrogen or a C1-3 aliphatic group;
• and
• Ring A is a pyrimidine ring wherein:
• Ring A is substituted with 0-3 groups independently selected from R′, oxo, CO2R′, OR′, N(R′)2, SR′, NO2, halogen, CN, C(O)N(R′)2, NR′C(O)R′, SO2R′, SO2N(R′)2, or NR′SO2R′.